Nonthymoma early-onset- and late-onset-generalized myasthenia gravis - A retrospective hospital-based study

被引:14
作者
Chan, K. H. [1 ]
Cheung, R. T. E. [1 ]
Mak, W. [1 ]
Ho, S. L. [1 ]
机构
[1] Univ Dept Med, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
关键词
nonthymoma-generalized myasthenia gravis; acetylcholine receptor autoantibodies; late-onset myasthenia gravis; early-onset myasthneia gravis; striated muscle autoantibodies;
D O I
10.1016/j.clineuro.2007.05.023
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Acquired myasthenia gravis (MG) is predominantly due to nicotinic acetylcholine receptor (AChR) autoantibodies (Ab). Differences between nonthymoma early-onset and late-onset MG were reported. We studied the clinical and serological characteristics of nonthymoma AChR Ab-positive-generalized MG patients. Patients and methods: Chinese AChR Ab-positive-generalized MG patients who had generalized disease for 3 years or longer were studied. Results: Among 41 such patients, 25 (61%) were female. The mean onset age was 43.5 years (range 9-78 years) and the mean follow-up duration was 7.8 years (range 3-20 years). Sixteen (39%) patients had late-onset disease (onset age >= 50 years). Compared to early-onset patients (onset age < 50 years), late-onset patients were characterized by male predominance (p = 0.002), absence of thymic lymphofollicular hyperplasia (p = 0.036), and a higher striated muscle Ab seropositivity rate (94% versus 4%, p < 0.001). Although there was no statistically significant difference in clinical severity and outcome or response to treatment between late-onset and early-onset patients, 50% and 75% of late-onset patients had moderate or severe disease at onset and worst status, respectively, compared to 28% and 52% for early-onset patients at onset and worst status, respectively. Also 63% of late-onset patients had disease progressed within first 3 years compared to only 40% of early-onset patients did. Conclusion: Nonthymoma late-onset-generalized MG patients were common among Hong Kong Chinese, with a statistically non-significant trend that it was clinically more severe than early-onset MG but with similar clinical outcome or response to treatment; > 90% of these patients were seropositive for striated muscle Ab. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:686 / 691
页数:6
相关论文
共 34 条
[1]
Inflammatory myopathy in myasthenia gravis [J].
Aarli, JA .
CURRENT OPINION IN NEUROLOGY, 1998, 11 (03) :233-234
[2]
Late onset myasthenia gravis [J].
Aarli, JA .
EUROPEAN JOURNAL OF NEUROLOGY, 1997, 4 (03) :203-209
[3]
ASSOCIATION OF HLA-BW46DR9 COMBINATION WITH JUVENILE MYASTHENIA-GRAVIS IN CHINESE [J].
CHEN, WH ;
CHIU, HC ;
HSEIH, RP .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1993, 56 (04) :382-385
[4]
Factors influencing improvement and remission rates after thymectomy for myasthenia gravis [J].
de Perrot, M ;
Licker, M ;
Spiliopoulos, A .
RESPIRATION, 2001, 68 (06) :601-605
[5]
THE RELATIONSHIP OF AGE TO OUTCOME IN MYASTHENIA-GRAVIS [J].
DONALDSON, DH ;
ANSHER, M ;
HORAN, S ;
RUTHERFORD, RB ;
RINGEL, SP .
NEUROLOGY, 1990, 40 (05) :786-790
[6]
MEDICAL PROGRESS - MYASTHENIA-GRAVIS [J].
DRACHMAN, DB .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (25) :1797-1810
[7]
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis [J].
Evoli, A ;
Tonali, PA ;
Padua, L ;
Lo Monaco, M ;
Scuderi, F ;
Batocchi, AP ;
Marino, M ;
Bartoccioni, E .
BRAIN, 2003, 126 :2304-2311
[8]
THYMECTOMY FOR THE MYASTHENIA-GRAVIS PATIENT - FACTORS INFLUENCING OUTCOME [J].
FRIST, WH ;
THIRUMALAI, S ;
DOEHRING, CB ;
MERRILL, WH ;
STEWART, JR ;
FENICHEL, GM ;
BENDER, HW .
ANNALS OF THORACIC SURGERY, 1994, 57 (02) :334-338
[9]
GRIESMANN GE, 1997, MANUAL CLIN LAB IMMU, P983
[10]
Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology [J].
Gronseth, GS ;
Barohn, RJ .
NEUROLOGY, 2000, 55 (01) :7-15